Professional
Added to YB: 2026-07-14
Pitch date: 2026-07-12
NKTR [neutral]
Nektar Therapeutics
-45.89%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Market Cap
$1.4B
Pitch Price
$69.71
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.43
P/E
-6.53
EV/Sales
16.36
Sector
Biotechnology
Category
growth
Show full summary:
Cedar Grove Capital Management Portfolio Holding: Nektar Therapeutics
NKTR (holding update): Positive alopecia-areata data in April validated rezpegaldesleukin (rezpeg) in a second indication. Shares +50% on news but retraced to near original cost basis. Data broadened opportunity, strengthening long-term thesis. Remaining patient as program advances.
Read full article (1 min)